As reported on Fierce Pharma, Huyabio has reported encouraging Phase 3 results for its investigational oral HDAC inhibitor, HBI-8000, when used alongside Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) in patients with advanced melanoma. The trial, the largest cancer study conducted by the company in its history, met its primary goal by demonstrating a meaningful improvement in progression-free survival.
The multinational study enrolled 404 patients from 15 countries and compared the combination of HBI-8000 plus Opdivo against Opdivo with placebo. Patients receiving the experimental regimen achieved a median progression-free survival of 11.7 months, while those in the control arm reached 7.4 months. The improvement, representing a 58% increase, was statistically significant.
The findings suggest that adding HBI-8000 to immune checkpoint inhibition may further enhance outcomes for patients with advanced melanoma, a particularly aggressive form of skin cancer. Despite substantial advances made with immunotherapies over the past decade, many patients still experience disease progression, underscoring the need for additional treatment options.
Huyabio stated that the positive Phase 3 outcome moves the company closer to introducing a potential first-line therapy for advanced melanoma. Additional analyses are currently being conducted to better understand the magnitude and nature of the treatment benefit observed in the study.
Commenting on the results, Huyabio Chief Executive Officer Mireille Gillings, PhD, described the data as an important advancement for both patients and the melanoma treatment landscape. She noted that while immunotherapy has significantly improved survival rates, considerable unmet need remains, and she believes HBI-8000 could become a valuable component of standard melanoma care.
The company, which has operations in San Diego and Shanghai, plans to present the complete trial results at a forthcoming medical meeting. Details regarding potential regulatory submissions or approval timelines have not yet been disclosed.
How HBI-8000 Works
HBI-8000 is a histone deacetylase (HDAC) inhibitor that influences gene activity through epigenetic mechanisms. The therapy is designed to restore the function of genes that suppress tumor growth, slow the proliferation of cancer cells, and increase the ability of the immune system to recognize and attack tumors. These effects may enhance the activity of checkpoint inhibitors such as Opdivo, potentially leading to stronger anti-cancer responses.
Previous Regulatory Approvals
The drug already holds several approvals in Asian markets. HBI-8000 was authorized as a standalone treatment for T-cell lymphoma in China in 2014 and later in Japan in 2021. In addition, it received approval in combination with an aromatase inhibitor for breast cancer treatment in China in 2019 and in Taiwan in 2023.
With these latest Phase 3 melanoma results, HBI-8000 could emerge as a promising addition to immunotherapy-based treatment approaches if future analyses and regulatory evaluations continue to support its clinical benefit.
